Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
July 26, 2024 / MASLD / Liver Disease Treatment
A study identifies ferroptosis, an iron-catalyzed cell death, as a detrimental factor in metabolic dysfunction-associated steatotic liver disease (MASLD). Inhibiting ferroptosis with UAMC-3203 showed promise in reducing liver damage, suggesting a new therapeutic target for MASLD.
American Heart Association Launches Cardiovascular-Kidney-Metabolic Health Initiative
July 25, 2024 / CKM Syndrome / AHA / Cardiovascular-Kidney-metabolic Health
The American Heart Association launched a 4-year Cardiovascular-Kidney-Metabolic Health Initiative to standardize the prevention, screening, and treatment of CKM syndrome, involving collaboration with key health organizations and engagement with 150 hospitals and 265,000 patients.
Artificial intelligence chatbots for the nutrition management of diabetes and the metabolic syndrome
July 26, 2024 / AI Chatbots / Healthcare / Nutrition Management / Diabetes / Metabolic Syndrome
A study evaluating ChatGPT’s effectiveness in nutritional management for Type 2 Diabetes and Metabolic Syndrome found gaps in recommendations for weight loss, energy deficit, specific nutrients, and physical activity, though overall clarity was rated good to excellent.
Expanding APAC presence, Insilico Medicine seals strategic collaboration on AI-driven mash therapy development with Korean Biotech Therasid Bioscience
July 23, 2024 / Insilico Medicine Collaboration / AI / Metabolic Dysfunction
Insilico Medicine and Therasid Bioscience have partnered to use AI-driven technology to develop novel therapies for metabolic dysfunction-associated steatohepatitis (MASH), leveraging Insilico’s Pharma.AI platform and Therasid’s expertise to accelerate drug discovery and development.
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
July 25, 2024 / Obesity / Metabolic Complications / ZyVersa Therapeutics
ZyVersa Therapeutics selects obesity and related metabolic complications as the lead indication for their inflammasome ASC inhibitor IC 100, aiming to reduce chronic inflammation and improve metabolic health in patients with obesity.
New research in fatty liver disease aims to help with early intervention
July 25, 2024 / Fatty Liver Disease / Metabolic Dysfunction / MASH Pathology
New research aims to enhance understanding of the pathology of metabolic dysfunction-associated steatohepatitis (MASH), potentially aiding in early intervention and treatment strategies for fatty liver disease.
Study identifies metabolic inflexibility that keeps damage at bay during liver regeneration
July 26, 2024 / Metabolic Health / Cardiovascular Risk
A 10-year study found that shift workers had higher BMI, FBS, triglycerides, liver enzymes, and blood pressure compared to day workers, indicating shift work’s negative impact on metabolic and cardiovascular health.
Weight-loss surgery appears to benefit patients with heart failure, obesity
July 23, 2024 / Weight-Loss / Heart Failure Treatment / BMI Reduction
Weight-loss surgery improves outcomes in heart failure patients with obesity, reducing BMI, HbA1c, and reliance on diuretics over 24 months, with trends toward fewer emergency visits.
Nayanthara promotes hibiscus tea as a cure-all for diabetes, acne and more but doctor advises caution
July 29, 2024 / Hibiscus Tea / Diabetes / Antioxidants
Actor Nayanthara promoted hibiscus tea for various health benefits, but Dr. Subrata Das advises caution, noting that while hibiscus tea has antioxidants and potential benefits, its effects on blood pressure and cholesterol need more research, and it may interact with medications.
Dietary changes may treat obesity by giving mitochondria a boost
July 28, 2024 / Obesity / Fasting / Clinical Trials / Mexico
A clinical trial in Mexico found that calorie-restricted, intermittent fasting, and ketogenic diets improve mitochondrial function in monocytes, potentially aiding weight loss and reducing inflammation in individuals with obesity.
Study finds obese patients have more neutrophils than those who are not obese
July 24, 2024 / Obesity / Metabolic Disorders / Gut Microbiome
A study reveals that obese individuals have more neutrophils in visceral adipose tissue, linking these immune cells to chronic inflammation and metabolic disorders. The findings suggest potential therapeutic targets for obesity-related complications.
Research helps show which type 2 diabetes medication may work best
July 23, 2024 / Type 2 Diabetes / Medication Comparison / Insulin
New research from the University of Colorado, published in Diabetes Care, delves into the GRADE study data to compare the effectiveness of four type 2 diabetes medications—insulin glargine, liraglutide, glimepiride, and sitagliptin—helping providers choose the best treatment for patients.
Early-Stage GLP-1 Win in Obesity; An Argument for BMI’s Value; Insulin Supply Issues
July 23, 2024 / GLP-1 Agonists / BMI Value / Obesity Treatment / Insulin Supply
A Phase I trial showed a 6.1% placebo-adjusted weight loss with the oral GLP-1 agonist CT-996. BMI remains valuable for defining obesity. Insulin supply issues persist amid increasing interest in GLP-1 agonists.
How diet affects metabolism and the gut microbiome
July 28, 2024 / Gut Microbiome / Metabolic Health / Mediterranean Diet / Fasting
A University of Eastern Finland study found that a higher exposome score, combining various environmental and lifestyle factors, correlates with changes in 31 serum metabolites linked to cardiometabolic health in children, highlighting the composite score’s predictive value.
Xanthones show promise in diabetes with antioxidant and anti-inflammatory properties
July 29, 2024 / Xanthones / Antidiabeteic Effects / Diabetes Management / Insulin Sensitivity
Xanthones, natural polyphenolic compounds, show antidiabetic potential by enhancing insulin sensitivity, modulating glucose metabolism, and providing antioxidant and anti-inflammatory benefits, potentially improving management of diabetes and its complications.
Professors Weigh In on the Obesity Breakthrough of Ozempic and Similar Drugs
July 29, 2024 / GLP-1 Agonists / Obesity / Ozempic / Weight Loss
Rutgers professors discuss the breakthrough impact of GLP-1 agonists like Ozempic in treating obesity, emphasizing the importance of combining medication with high-fiber diets to enhance weight loss and improve metabolic health.
Kidney outcomes are altered by preconception weight modulation in rodent mothers with obesity
July 29, 2024 / Women’s Health / Kidney Health / Obesity / Weight Loss
Preconception weight loss, through diet modification or liraglutide treatment, improves maternal kidney outcomes in obese mice, reducing oxidative stress and protein expression of fibrosis markers compared to weight interventions initiated during pregnancy.
Genome-scale community modelling elucidates the metabolic interaction in Indian type-2 diabetic gut microbiota
July 27, 2024 / Type 2 Diabetes / Gut Microbiota / Metabolic Interation / T2D Biomakers
A study using genome-scale community modeling reveals distinct metabolic interactions in the gut microbiota of Indian type-2 diabetes patients. Findings show reduced metabolic flux of acetate, butyrate, and vitamins, potentially impacting carbohydrate metabolism and highlighting potential biomarkers for T2D.
ZyVersa selects obesity, related metabolic implications at lead indication
July 25, 2024 / ASC Inhibitor / Obesity Treatment / Metabolic Complications / ZyVera Therapeutics
ZyVersa Therapeutics selects obesity and related metabolic complications as the lead indication for Inflammasome ASC Inhibitor IC 100, aiming to reduce chronic inflammation and enhance weight loss in combination with GLP-1 agonists.